Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2015
  • Internal Medicine Chief Resident, Medicine, Duke University School of Medicine 2012 - 2013
  • Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., Indiana University School of Medicine 2008
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
  • Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2012 - 2013
• Research
• 

  Selected Grants

  • TOP 1705 awarded by Bristol-Myers Squibb Company 2018 - 2023
  • SPI-POZ-202 awarded by Spectrum Pharmaceuticals, Inc 2017 - 2022
  • M15-534 awarded by AbbVie Inc. 2017 - 2022
  • Bayer 16044 awarded by Bayer HealthCare AG 2017 - 2021
  • A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance awarded by Adaptimmune Limited 2016 - 2021
  • Genentech GO29537 awarded by F. Hoffmann-La Roche Ltd 2015 - 2020
  • A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors awarded by Bristol-Myers Squibb Company 2015 - 2020
  • mRNA-4157-P101 awarded by Moderna Therapeutics, Inc. 2017 - 2019
  • Adaptimmune MAGE awarded by Adaptimmune Limited 2018 - 2019
  • First-in-human dose escalation of TEW-7197 monotherapy in subjects with advanced stage solid tumors awarded by MedPacto, Inc 2014 - 2019
  • A phase Ib study of combination Regorafenib with PF-03446962 in patient with refactory metastatic colorectal cancer or G awarded by Pfizer, Inc. 2013 - 2019
  • Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer awarded by V Foundation for Cancer Research 2016 - 2018
  • Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer awarded by Lung Cancer Initiative of North Carolina 2015 - 2018
  • Lilly H9H-MC-JBEF awarded by Eli Lilly and Company 2016 - 2018
  • Blood-based Biomarker Profiling for TEW-7197 awarded by MedPacto, Inc 2016 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • DeMaio, A, Clarke, JM, Dash, R, Sebastian, S, Wahidi, MM, Shofer, SL, Cheng, GZ, Li, X, Wang, X, and Mahmood, K. "Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma." Journal of Bronchology & Interventional Pulmonology (July 25, 2018).  Full Text
    • Clarke, JM, George, DJ, Lisi, S, and Salama, AKS. "Immune Checkpoint Blockade: The New Frontier in Cancer Treatment." Targeted oncology 13, no. 1 (February 13, 2018): 1-20.  Full Text
    • Yi, JS, Ready, N, Healy, P, Dumbauld, C, Osborne, R, Berry, M, Shoemaker, D, Clarke, J, Crawford, J, Tong, B, Harpole, D, D'Amico, TA, McSherry, F, Dunphy, F, McCall, SJ, Christensen, JD, Wang, X, and Weinhold, KJ. "Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7474-7482.  Full Text
    • Bedoya, A, Glisinski, K, Clarke, J, Lind, RN, Buckley, CE, and Shofer, S. "Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases." The American Journal of Case Reports 18 (July 31, 2017): 842-846.  Full Text
    • Clarke, JM, Wang, X, and Ready, NE. "Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?." Translational Lung Cancer Research 4, no. 6 (December 2015): 804-808.  Full Text
    • Hatch, AJ, Clarke, JM, Nixon, AB, and Hurwitz, HI. "Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress." Cancer journal (Sudbury, Mass.) 21, no. 4 (July 2015): 322-326. (Review)  Full Text
    • Lyman, GH, Bohlke, K, Khorana, AA, Kuderer, NM, Lee, AY, Arcelus, JI, Balaban, EP, Clarke, JM, Flowers, CR, Francis, CW, Gates, LE, Kakkar, AK, Key, NS, Levine, MN, Liebman, HA, Tempero, MA, Wong, SL, Somerfield, MR, Falanga, A, and American Society of Clinical Oncology, . "Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 6 (February 2015): 654-656.  Full Text
    • Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective." Cancer treatment reviews 40, no. 9 (October 2014): 1065-1072. (Review)  Full Text
    • Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician's perspective." Cancer Treatment Reviews 40, no. 9 (2014): 1065-1072.  Full Text
    • Clarke, JM, and Hurwitz, HI. "Understanding and targeting resistance to anti-angiogenic therapies." J Gastrointest Oncol 4, no. 3 (September 2013): 253-263.  Full Text  Link to Item
    • Clarke, JM, and Hurwitz, HI. "Targeted inhibition of VEGF receptor 2: an update on ramucirumab." Expert Opinion on Biological Therapy 13, no. 8 (August 2013): 1187-1196. (Review)  Full Text
    • Lyman, GH, Khorana, AA, Kuderer, NM, Lee, AY, Arcelus, JI, Balaban, EP, Clarke, JM, Flowers, CR, Francis, CW, Gates, LE, Kakkar, AK, Key, NS, Levine, MN, Liebman, HA, Tempero, MA, Wong, SL, Prestrud, AA, Falanga, A, and American Society of Clinical Oncology Clinical Practice, . "Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 17 (June 2013): 2189-2204. (Review)  Full Text
    • Clarke, JM, and Armstrong, AJ. "Novel therapies for the treatment of advanced prostate cancer." Curr Treat Options Oncol 14, no. 1 (March 2013): 109-126. (Review)  Full Text  Link to Item
    • Mis, L, and Clarke, JM. "Ipilimumab-Induced Pneumonitis: A Case Report." Journal of Pharmacy Technology 29, no. 2 (March 2013): 94-98.  Full Text
    • Clarke, JM, and Hurwitz, HI. "Ziv-aflibercept: binding to more than VEGF-A--does more matter?." Nature Reviews. Clinical Oncology 10, no. 1 (January 2013): 10-11.  Full Text
    • Clarke, JM, Morse, MA, Lyerly, HK, Clay, T, and Osada, T. "Adenovirus vaccine immunotherapy targeting WT1-expressing tumors." Expert Opin Biol Ther 10, no. 6 (June 2010): 875-883. (Review)  Full Text  Link to Item
    • Clarke, JM, and Helft, P. "Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: A case report and review of the literature." Journal of Medical Case Reports 4 (2010).  Full Text
    • Struck, A, Howard, T, Chiorean, EG, Clarke, JM, Riffenburgh, R, and Cardenes, HR. "Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival." Journal of Surgical Oncology 100, no. 2 (August 2009): 144-148.  Full Text
    • Struck, A, Howard, T, Chiorean, EG, Clarke, JM, Riffenburgh, R, and Cardenes, HR. "Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival (Journal of Surgical Oncology (2009) 100, 2, (144-148))." Journal of Surgical Oncology 100, no. 5 (2009): 434--.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.